AR099569A1 - Derivados de insulina y los usos médicos de estos - Google Patents

Derivados de insulina y los usos médicos de estos

Info

Publication number
AR099569A1
AR099569A1 ARP150100559A ARP150100559A AR099569A1 AR 099569 A1 AR099569 A1 AR 099569A1 AR P150100559 A ARP150100559 A AR P150100559A AR P150100559 A ARP150100559 A AR P150100559A AR 099569 A1 AR099569 A1 AR 099569A1
Authority
AR
Argentina
Prior art keywords
derivatives
insulin derivatives
medical uses
diabetes
refers
Prior art date
Application number
ARP150100559A
Other languages
English (en)
Inventor
Fledelius Christian
Madsen Peter
Horstrup Susanne
Mnzel Martin
Brglum Kjeldsen Thomas
Ulrik Hjrringgaard Claudia
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR099569A1 publication Critical patent/AR099569A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente pertenece al campo terapéutico de fármacos para afecciones médicas relacionadas con la diabetes. Más específicamente, se refiere a derivados acilados de análogos de la insulina humana. También proporciona composiciones farmacéuticas que comprenden este tipo de derivados de insulina, y se refiere al uso de este tipo de derivados para el tratamiento o prevención de afecciones médicas relacionadas con la diabetes.
ARP150100559A 2014-02-28 2015-02-25 Derivados de insulina y los usos médicos de estos AR099569A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14157215 2014-02-28

Publications (1)

Publication Number Publication Date
AR099569A1 true AR099569A1 (es) 2016-08-03

Family

ID=50184804

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100559A AR099569A1 (es) 2014-02-28 2015-02-25 Derivados de insulina y los usos médicos de estos

Country Status (23)

Country Link
US (1) US10040839B2 (es)
EP (1) EP3110840B1 (es)
JP (1) JP6580583B2 (es)
KR (1) KR20160125988A (es)
CN (1) CN106459171B (es)
AR (1) AR099569A1 (es)
AU (1) AU2015222135B2 (es)
BR (1) BR112016017193A2 (es)
CA (1) CA2941103A1 (es)
DK (1) DK3110840T3 (es)
ES (1) ES2831848T3 (es)
HR (1) HRP20201732T1 (es)
HU (1) HUE051355T2 (es)
IL (1) IL246757B (es)
MX (1) MX368387B (es)
PL (1) PL3110840T3 (es)
PT (1) PT3110840T (es)
RS (1) RS61137B1 (es)
RU (1) RU2684456C2 (es)
SA (1) SA516371705B1 (es)
SI (1) SI3110840T1 (es)
TW (1) TWI686403B (es)
WO (1) WO2015128403A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170028031A1 (en) * 2014-03-07 2017-02-02 Klavs Holger Jørgensen Novel fast acting insulin preparations
JP2018531900A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
CN110198722A (zh) * 2016-11-21 2019-09-03 卡斯西部储备大学 稳定性增强的快速作用的胰岛素类似物
KR101909052B1 (ko) * 2017-02-09 2018-10-17 강원대학교산학협력단 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물
WO2018185131A2 (en) * 2017-04-05 2018-10-11 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
EP3668892A1 (en) * 2017-08-17 2020-06-24 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
MX2020004251A (es) * 2017-10-19 2021-05-27 Mona E Buice Composición tópica para cicatrización mejorada de heridas abiertas.
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
AU2019398402A1 (en) 2018-12-11 2021-07-29 Sanofi Insulin analogs having reduced insulin receptor binding affinity
WO2020166592A1 (ja) * 2019-02-13 2020-08-20 大日本住友製薬株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
KR20220066287A (ko) * 2019-08-27 2022-05-24 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이의 의약 용도
CN114787184A (zh) 2019-12-11 2022-07-22 诺和诺德股份有限公司 新型胰岛素类似物及其用途
AU2022283328A1 (en) * 2021-05-24 2023-11-16 Sunshine Lake Pharma Co., Ltd. A novel acylated insulin analog

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
KR910700262A (ko) * 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
DE69019534T2 (de) * 1989-12-21 1995-09-21 Novo Nordisk As Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten.
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
ATE204882T1 (de) 1993-09-17 2001-09-15 Novo Nordisk As Acyliertes insulin
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
BR9607647A (pt) 1995-03-17 1999-04-06 Novo Nordisk As Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
WO1998042749A1 (en) 1997-03-20 1998-10-01 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
EP1039920A4 (en) 1997-10-24 2003-05-28 Lilly Co Eli INSULIN ANALOGS ACYLATED BY FATTY ACID
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
PL195845B1 (pl) 1997-10-24 2007-10-31 Novo Nordisk As Rozpuszczalny w wodzie agregat pochodnych insuliny
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
JP2002518408A (ja) 1998-06-12 2002-06-25 キングス・カレツジ・ロンドン インスリン類似体
EP1196446A1 (en) 1999-06-29 2002-04-17 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
AU2001264789A1 (en) 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
JP2005526009A (ja) 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
EP1545460A4 (en) 2001-12-20 2005-11-16 Lilly Co Eli INSULIN MOLECULE WITH TEMPORARY EFFECT
AU2003208316A1 (en) 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
KR20050121748A (ko) 2003-04-29 2005-12-27 일라이 릴리 앤드 캄파니 연장된 시간 작용을 갖는 인슐린 유사체
US20060183667A1 (en) 2003-07-11 2006-08-17 Novo Nordisk A/S Stabilised insulin compositions
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
CN102552917A (zh) 2003-08-13 2012-07-11 比奥孔有限公司 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
ES2369895T3 (es) 2003-12-03 2011-12-07 Novo Nordisk A/S Insulina monocatenaria.
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
CA2580313C (en) 2004-07-19 2016-03-15 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
US20100216690A1 (en) 2005-03-18 2010-08-26 Novo Nordisk A/S Pegylated Single-Chain Insulin
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
KR101441444B1 (ko) 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 인슐린 유도체
US8900555B2 (en) 2006-07-27 2014-12-02 Nektar Therapeutics Insulin derivative formulations for pulmonary delivery
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
KR101699370B1 (ko) * 2006-09-22 2017-02-14 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
WO2009015456A1 (en) 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
EP2178912B1 (en) * 2007-08-15 2015-07-08 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
US8710000B2 (en) 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
ES2430042T3 (es) 2007-11-16 2013-11-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
NZ584825A (en) 2007-11-20 2013-03-28 Ambrx Inc Modified insulin polypeptides and their uses
EP2254905B1 (en) * 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
WO2009115469A1 (en) * 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
EP2448962B1 (en) 2009-06-30 2016-10-19 Novo Nordisk A/S Insulin derivatives
RU2556340C2 (ru) * 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Композиция инсулина длительного действия
WO2011141407A1 (en) 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
CA2802510A1 (en) * 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
WO2011161124A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
WO2012010553A1 (en) 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
WO2012171994A1 (en) * 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
WO2013063572A1 (en) 2011-10-27 2013-05-02 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations

Also Published As

Publication number Publication date
PT3110840T (pt) 2020-11-26
US20170008945A1 (en) 2017-01-12
DK3110840T3 (da) 2020-11-02
MX2016010899A (es) 2016-11-18
JP6580583B2 (ja) 2019-09-25
CN106459171A (zh) 2017-02-22
MX368387B (es) 2019-10-01
SA516371705B1 (ar) 2019-10-08
TW201620930A (zh) 2016-06-16
CA2941103A1 (en) 2015-09-03
IL246757A0 (en) 2016-08-31
WO2015128403A3 (en) 2015-12-10
RU2016135543A (ru) 2018-03-30
RU2016135543A3 (es) 2018-08-30
JP2017508741A (ja) 2017-03-30
AU2015222135A1 (en) 2016-07-28
ES2831848T3 (es) 2021-06-09
RU2684456C2 (ru) 2019-04-09
US10040839B2 (en) 2018-08-07
EP3110840A2 (en) 2017-01-04
HRP20201732T1 (hr) 2020-12-25
AU2015222135B2 (en) 2018-12-20
CN106459171B (zh) 2020-12-15
KR20160125988A (ko) 2016-11-01
BR112016017193A2 (pt) 2017-10-03
HUE051355T2 (hu) 2021-03-01
WO2015128403A2 (en) 2015-09-03
SI3110840T1 (sl) 2020-12-31
EP3110840B1 (en) 2020-10-21
PL3110840T3 (pl) 2021-04-06
RS61137B1 (sr) 2020-12-31
IL246757B (en) 2020-04-30
TWI686403B (zh) 2020-03-01

Similar Documents

Publication Publication Date Title
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
ECSP20040257A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
DOP2016000271A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
AR106364A1 (es) Derivados de insulina y sus usos médicos
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
CO2019006017A2 (es) Composiciones farmacéuticas que contienen insulina
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
SV2016005330A (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cã�ncer
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
BR112016027435A2 (pt) formulação inovadora de meloxicam
EA201692278A1 (ru) Комбинации формотерола и будесонида для лечения хобл
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina